Neurocrine Biosciences (NBIX) Stock Analysis & AI Equity Report
Neurocrine Biosciences (NBIX) overview
Neurocrine Biosciences (NBIX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 2,861m and operating profit of USD 619m; the year-end share price was 141.83 USD and market capitalisation was USD 14,197m. Neurocrine Biosciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Neurocrine Biosciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Neurocrine Biosciences
Neurocrine Biosciences discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders. Its marketed products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease, and CRENESSITY for classic congenital adrenal hyperplasia. It also collaborates with AbbVie on treatments for endometriosis and uterine fibroids, and sells products through specialty pharmacy providers, wholesale distributors, and specialty distributors.
Generate the Neurocrine Biosciences report
Neurocrine Biosciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Neurocrine Biosciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Neurocrine Biosciences
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.